Streetbeat News

Price Targets

RGTI

Needham analyst Quinn Bolton maintains a 'Buy' rating on Rigetti Computing (NASDAQ:RGTI) and raises the price target from $1 to $3.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:56 am

LUNA

Needham analyst Alex Henderson has reiterated a 'Buy' rating on Luna Innovations (NASDAQ:LUNA) and maintained a price target of $10.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:55 am

CPRI

Telsey Advisory Group has maintained a 'Market Perform' rating on Capri Holdings (NYSE:CPRI) and raised the price target from $41 to $57.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:54 am

SYBX

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Synlogic (NASDAQ:SYBX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:52 am

OPFI

Needham analyst Mayank Tandon has reiterated a 'Buy' rating on OppFi (NYSE:OPFI) and maintained a price target of $3.5.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:52 am

AKBA

HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:51 am

PMVP

HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on PMV Pharma (NASDAQ:PMVP), but has lowered the price target from $35 to $29.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:50 am

TNGX

HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Tango Therapeutics (NASDAQ:TNGX) and raises the price target from $11 to $16.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:49 am

THMO

HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on ThermoGenesis Holdings (NASDAQ:THMO) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:48 am

HOOK

HC Wainwright & Co. analyst Arthur He maintains a 'Buy' rating on HOOKIPA Pharma (NASDAQ:HOOK) but lowers the price target from $8 to $6.5.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 10:47 am